Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

China's deadly drug problem

The head of China's drug-safety agency is under investigation for alleged corruption. David Cyranoski looks at how the inquiry might affect the country's fast-growing pharmaceutical industry.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Related links

Related links

Related links in Nature Research

Can China bring its own pipeline to the market?

Chinese biotech hamstrung by production issues

Poor enforcement could jeopardize China's drug innovation policy

Handle with care

Related external links

State Food and Drug Administration P.R China

The National Center for Drug Screening

Rights and permissions

Reprints and Permissions

About this article

Cite this article

China's deadly drug problem. Nature 446, 598–599 (2007). https://doi.org/10.1038/446598a

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/446598a

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing